A new spring-driven syringe pump (Springfusor 1O®, Go Medical Industries, Subiaco, WA.) was evaluated for infusion of muscle relaxants in 50 surgical cases. After an initial bolus dose, atracurium was given at a rate of 25 to 37.5 The Springfusor® is a new syringe infusion pump designed and made in Australia. It consists of a springloaded cartridge which drives a 10 ml syringe. The output from the syringe is controlled by a short length of narrow bore flow control tubing. The Springfusor, syringe and flow control tubing, prepared ready for use, are shown in Figure 1 . Due to their short duration of action, modern muscle relaxants lend themselves to use by continuous infusion. 1_4 The aim of this trial was to assess the suitability of the Springfusor for the infusion of muscle relaxants during surgery. 
The Springfusor® is a new syringe infusion pump designed and made in Australia. It consists of a springloaded cartridge which drives a 10 ml syringe. The output from the syringe is controlled by a short length of narrow bore flow control tubing. The Springfusor, syringe and flow control tubing, prepared ready for use, are shown in Figure 1 . Due to their short duration of action, modern muscle relaxants lend themselves to use by continuous infusion. 1_4 The aim of this trial was to assess the suitability of the Springfusor for the infusion of muscle relaxants during surgery.
MATERIALS AND METHODS
The Springfusor provides a fixed-rate continuous infusion. A range of non-kink flow control tubing is available to achieve flow rates from 10 ml/5 min to 10 mll8 hours. Flow rate from each is fixed and accuracy is claimed to be ± 20070 at 20 DC. The force generated by the compression spring in the Springfusor decreases during infusion, such that flow rate is 10070 above the mean at the start and 10070 below the mean at the end of the infusion.
The rate of flow from the flow control tubing is given by the Poiseuille equation. s It is dependent upon the fluid pressure in the syringe (which is determined by the difference between the spring force and syringe friction) and the internal diameter of the flow control tube, and inversely dependent upon the length of the flow control tube and the fluid viscosity. Syringe brands which can be used with the Springfusor are limited to those with low, repeatable plunger friction such as Talus, Braun and Asik. Talus (Livingston International, Sydney) brand 10 mlluer lock syringes were used. Dilute aqueous solutions such as muscle relaxant injections do not require viscosity correction, but a table of correction factors for other drug solutions is provided by the manufacturer. Temperature also affects viscosity of the injection fluid. For each degree Celsius above or below 20 DC, the flowrate increases or decreases respectively by approximately 2.5070. If necessary, the expected infusion time can be corrected for temperature.
The Springfusor was used during 50 adult cases undergoing a variety of surgical procedures lasting one to five hours. The only requirement for inclusion was a need for prolonged muscle relaxation. Three Springfusor pumps were used during the trial.
The muscle relaxant used was either atracurium (n = 23) or vecuronium (n = 27). Flow control tubing delivering 5 mllhr (labelled 10 mll2 hr) was chosen. Atracurium was diluted with water for injection to a concentration of 5 to 7.5 mg/ml (dependent on the weight of the patient and degree of muscular relaxation required), giving a dose rate of 25 to 37.5 mg/hour. Similarly, vecuronium was used in a concentration of O.S to 1.2 mg/m, which provided an infusion rate of 4 to 6 mg/hour. Muscle relaxation was monitored in each case with a nerve stimulator. In the case of intraabdominal surgery, the suppression of three out of four twitches in a train-of-four was the goal; in surgery less demanding of muscle relaxation, an obvious fade in the train-of-four was acceptable.
Anaesthesia was induced in the usual way. After an initial bolus dose of muscle relaxant, appropriate to the operation, the infusion was commenced. A needle was attached to the flow control tubing and pushed through the injection port of the IV line. If infusion was required for longer than two hours the syringe, when empty, was removed, refilled and replaced. About ten minutes before the end of the operation, the syringe pump was removed. The volume in the syringe at the beginning and end of the infusion time was recorded. Infusions lasted from nine minutes to 251 minutes. Residual muscle paralysis was reversed with atropine and neostigmine. Effective reversal was judged by return of four equal twitches in a train-of-four and clinical evidence of adequate muscle power (i.e. good grip, ability to lift head).
RESULTS
The mean rate of infusion for the 50 cases was 5.2 mllhr (SD 0.4), with a range of 4.2 to 6.0 mllhr. The mean rate was only 4070 above the nominal rate of 5 mllhr. The range was from -16070 to + 20070 of the nominal rate. The resultant level of muscle relaxation was found to be generally satisfactory. In five cases the addition of one or more bolus doses during infusion was required. In no case was it necessary to suspend the infusion because of excessive paralysis.
DISCUSSION
The Springfusor is an interesting device. It is easy to use, taking only a minute or two to set up. In contrast to most syringe pumps, it is cheap (cost is less than $20) and rugged to the point of near- indestructibility. The Springfusor is reusable and, if stored and used appropriately to avoid damaging the stainless steel spring, has a virtually unlimited life. The flow control tubing is disposable and costs $4.50.
The practical outcome of the trial was satisfactory. An even level of muscle relaxation was provided with a minimum of fuss. At times it was necessary to administer a bolus dose of muscle relaxant, e.g. before peritoneal closure. The reversal of muscle relaxation at the end of the operation was adequate in all cases.
The measured range of flow rate accuracy (-16070 to + 20070) was within the manufacturer's claim of ± 20070. The flowrates were biased to the high side of nominal because operating room temperature generally fluctuated about 21°C. Since flowrate is calibrated at 20°C, higher ambient temperatures result in faster flowrates. The slight decrease in infusion rate from compression to extension of the spring (i.e. start to finish of infusion) had no practical impact in this trial. Given the variability in patient response to muscle relaxants,',6 a disadvantage of the Springfusor is lack of infusion rate flexibility. A range of flow control tubing rates is available from 10 mll5 min to 10 mllS hours, but flow rate is fixed and dependent on the flow control tubing chosen. If a change in flowrate is required, the flow control tubing must be changed or the concentration of drug in the syringe altered. Alternatively, if the requirement for increased muscle relaxation is short term then a bolus dose can be given.
When the flow control tubing is in place, it is impossible to infuse the contents of the syringe rapidly. A bolus dose must be given through alternative access, such as a three-way tap, because it cannot be forced through the flow control tubing by hand. Care must be taken not to detach the flow control tubing from the syringe while it is still loaded, because the contents will be lost instantly and forcefully. Luer lock fittings are used to prevent accidental detachment. A potential problem, not encountered in this trial, is blockage of the flow control tubing by particles of poorly dissolved drugs or debris from ampoules. To maintain accuracy, choice of syringe brands which can be used with the Springfusor is limited to those with low frictional forces (Braun Omnifix®, Asik Primo® and Talus). The higher frictional forces of the more common syringe brands detract from the force exerted by the spring and thus result in slower flow rates.
CONCLUSION
The Springfusor is rugged, reliable, cheap and easy to use but lacks dose flexibility. It was found to be suitable for continuous background infusion of muscle relaxants during surgery.
